College students are abusing prescription drug Adderall says report on NBC's 'Today Show'

prescription drugs - BSN

(Best Syndication News) - An investigative report was aired on NBC’s “Today Show” which showed the epidemic problem on college students taking Adderall prescription medication because they believed that they would do better on tests. Adderall has been approved for treating ADHD and ADD disorders. The FDA said that this is a class II narcotic.

Adderall can be as addictive as illegal drugs said the “Today Show” report. They had an undercover camera show how easy it was to buy some Adderall on a college campus. They did not buy it, but the girl that was selling it explained how easy it was to get a prescription from the doctor for Adderall.

Dementia and Alzheimer's disease increased risk from being overweight and obese in middle age years

elderly man

(Best Syndication News) - Dementia increased in people that were overweight or obese during middle age years said a recent study that was published in the May 3, 2011 issue of the American Academy of Neurology's medical journal, 'Neurology.'

Weili Xu, MD, PhD, with the Karolinska Institutet in Stockholm, Sweden was the study's author, who along with colleagues, investigated data from the Swedish Twin Registry of 8,534 twins age 65 or older. The researcher found 350 people diagnosed with dementia and another 114 people who possibly had dementia. Also the research looked at the people's height and weight 30 years prior to see if there was a correlating risk factor for being overweight or obese and developing dementia.

TOPOMAX recall announced for two lots of prescription medication

TOPOMAX recall announced for two lots prescription medication

Best Syndication News

(Best Syndication News) - Two lots of TOPAMAX® (topiramate) 100mg dosage with 60 tablets in the bottle have been voluntarily recalled because of an unusual odor said the manufacturer, Ortho-McNeil Neurologics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. The smell they believe is related to a trace amount of TBA (2,4,6 tribromoanisole). The TBA could have come from a chemical preservative that is applied to wood such as the pallets that were used during transportation. The company received four consumers that reported the smell, which prompted the voluntary recall.

The recall involves around 57,000 bottles, but they believe there are less than 6,000 bottles that are in the marketplace. The two lots were shipped to US and Puerto Rico locations between October 19, 2010 and December 28, 2010.

Citalopram and Finasteride Recall announced because of label mixup says FDA

Citalopram and Finasteride Recall announced because of label mixup says FDA

Best Syndication News

(Best Syndication News) - The US Food and Drug Administration (FDA) announced a recall for citalopram and finasteride prescription medications because the wrong labels may have been put on these bottles mixing the two of them up. Greenston LLC, a subsidiary of Pfizer, is the manufacturers of these two medications that involved in this recall.

The list of recalled citalopram and finasteride prescription drugs are as follows:

• Citalopram 10 mg Tablets (100-count bottle), lot number FI0510058-A

• Finasteride 5 mg Tablets (90-count bottle), lot number FI0510058-A

Women taking Topamax topiramate prescription drug during pregnancy increases risk for Cleft Birth Defects

Women taking Topamax topiramate prescription drug during pregnancy increases risk for Infant Birth Defects

Best Syndication News

(Best Syndication News) - Women taking anti-convulsant medication, Topamax or the generic topiramate, during pregnancy have an increased risk for their baby to be born with birth defects in the mouth. These birth defects include cleft lip and cleft palate problems said the US Food and Drug Administration (FDA).

The North American Antiepileptic Drug (AED) Pregnancy Registry collected the data which showed the increased risk of oral clefts in babies that had mothers who had taken topiramate during the first trimester of the pregnancy. A single therapy exposure to the infant during gestation to the topiramate drug was 1.4 percent occurrence of developing an oral cleft birth defect compared with 0.38 percent – 0.55 percent of other anti-eplileptic drugs that were exposed to infants. Mothers that do not take any anti-convulsant medication had only a 0.07 percent prevalence of a cleft birth defect.

Syndicate content


Post to Facebook

Important: The material on Best Syndication is for informational purposes only and is not meant to be advice. Authors may have or will receive monetary compensation from the company's product/s mentioned. You should always seek professional advice before making any legal, financial or medical decisions and this website cannot substitute or replace any trained professional consultation.
Use of this site means that you agree to our TERMS OF SERVICE

Advertise On This Site
Copyright © 2006-2015 By Best Syndication All Rights Reserved